Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Jan Hendrik Rüschoff,Martina Haberecker,Zoi Tsourti,Kristiaan Nackaerts,Marc de Perrot,Luka Brcic,Ernest Nadal,Sotirios Tsimpoukis,Steven G Gray,Luca Ampollini,Joachim G Aerts,Emanuela Felley-Bosco,Michaela B Kirschner,Kim Monkhorst,Birgit Weynand,Fatemeh Bavaghar-Zaeimi,Miroslav Samarzija,Roger Llatjos,Stephen P Finn,Enrico Silini,Jan von der Thüsen,Nesa Marti,Karerina Vervita,Roswitha Kammler,Solange Peters,Rolf A Stahel,Paul Baas,Isabelle Opitz,ETOP Mesoscape consortium,Rolf Stahel,Anita Hiltbrunner,Rosita Kammler,Patrick Vagenknecht,Barbara Ruepp,Urania Dafni,Panagiota Zygoura,Katerina Vervita,Georgia Dimopoulou,Charitini Andriakopoulou,Androniki Stavrou,Jan H Rüschoff,Susanne Dettwiler,Fabiola Prutek,Christiane Mittmann,Bart Vrugt,Martina Friess,Alessandra Matter,Chloé Spichiger-Häusermann,Eric Verbeken,Birgit Weyenand,Liesbet Peeters,Marcello Tiseo,Enrico Maria Silini,Luigi Ventura,Letizia Gnetti,Paolo Carbognani,Fatemeh B Zaeimi,Sven Seiwerth,Marko Jakopovic,Felipe Cardenal,Susana Lorente,Konstantinos Syrigos,Ioannis Vamvakaris,Paraskevi Boura,Steven Gray,Mutaz Mohammed Nur,Anne-Marie Baird,Martin Barr,Sinead Cuffe,Kathy Gately,Joachim Aerts
DOI: https://doi.org/10.1038/s41379-022-01145-0
Abstract:Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Although histology and pathologic stage are important prognostic factors, better prognostic biomarkers are needed. The ribosomal protein S6 is a downstream target of the phosphatidylinositol 3-kinase (PI3K) pathway involved in protein synthesis and cell proliferation. In previous studies, low phosphorylated S6 (pS6) immunoreactivity was significantly correlated with longer progression-free survival (PFS) and overall survival (OS) in PM patients. We aimed to correlate pS6 expression to clinical data in a large multi-centre PM cohort as part of the European Thoracic Oncology Platform (ETOP) Mesoscape project. Tissue Micro Arrays (TMAs) of PM were constructed and expression of pS6 was evaluated by a semi-quantitatively aggregate H-score. Expression results were correlated to patient characteristics as well as OS/PFS. pS6 IHC results of 364 patients from 9 centres, diagnosed between 1999 and 2017 were available. The primary histology of included tumours was epithelioid (70.3%), followed by biphasic (24.2%) and sarcomatoid (5.5%). TMAs included both treatment-naïve and tumour tissue taken after induction chemotherapy. High pS6 expression (181 patients with H-score>1.41) was significantly associated with less complete resection. In the overall cohort, OS/PFS were not significantly different between pS6-low and pS6-high patients. In a subgroup analysis non-epithelioid (biphasic and sarcomatoid) patients with high pS6 expression showed a significantly shorter OS (p < 0.001, 10.7 versus 16.9 months) and PFS (p < 0.001, 6.2 versus 10.8 months). In subgroup analysis, in non-epithelioid PM patients high pS6 expression was associated with significantly shorter OS and PFS. These exploratory findings suggest a clinically relevant PI3K pathway activation in non-epithelioid PM which might lay the foundation for future targeted treatment strategies.